ID: ALA3981656

Max Phase: Preclinical

Molecular Formula: C28H33F4N3O6S

Molecular Weight: 501.62

Molecule Type: Small molecule

Representations

Canonical SMILES:  CS(=O)(=O)CC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)Cc1ccc(F)cc1.O=C(O)C(F)(F)F

Standard InChI:  InChI=1S/C26H32FN3O4S.C2HF3O2/c1-35(33,34)17-25(31)29(16-18-5-7-22(27)8-6-18)11-12-30-23-9-10-24(30)15-21(14-23)19-3-2-4-20(13-19)26(28)32;3-2(4,5)1(6)7/h2-8,13,21,23-24H,9-12,14-17H2,1H3,(H2,28,32);(H,6,7)/t21-,23+,24-;

Standard InChI Key:  SRLDYHPGRXASEQ-LLWNGYSHSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 501.62

Molecular Weight (Monoisotopic): 501.2098

AlogP: 2.71

#Rotatable Bonds: 9

Polar Surface Area: 100.78

Molecular Species: NEUTRAL

HBA: 5

HBD: 1

#RO5 Violations: 1

HBA (Lipinski): 7

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 8.55

CX Basic pKa: 7.06

CX LogP: 1.65

CX LogD: 1.61

Aromatic Rings: 2

Heavy Atoms: 35

QED Weighted: 0.57

Np Likeness Score: -1.25

References

1.  (2014)  8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists, 

Source

Source(1):

• Patent Bioactivity Data